Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Depression 4Neoplasms 3Anxiety Disorders 3Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Hematopoietic and Lymphatic System Neoplasm 1Gastrointestinal Neoplasms 1Depressive Disorder, Major 1Depressive Disorder 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Carboplatin 121pembrolizumab 119Pemetrexed 102Cisplatin 76Paclitaxel 56osimertinib 52Nivolumab 50Docetaxel 50durvalumab 47Specimen Handling 37Gemcitabine 34Magnetic Resonance Spectroscopy 33Radiosurgery 27Cetuximab 26130-nm albumin-bound paclitaxel 26atezolizumab 25Radiotherapy 20Ipilimumab 19Drug Therapy 19Bevacizumab 19cemiplimab 17amivantamab 17Taxes 16Ramucirumab 13alectinib 12tislelizumab 11lazertinib 11Leucovorin 11Fluorouracil 11Radiation 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × Psilocybin × 90 days × Clear all
NCT07216404 2026-05-14

Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
10 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Depressive Disorder

Data powered by HemOnc (CC BY 4.0) Colophon âš¡